Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Y Song
AddedFeb 15, 2024
UpdatedMay 31, 2026
Paul Y Song

Paul Y Song

Board Member, PeproMene Bio

CrunchbaseLinkedInThe Org

Paul Y Song's Career

PeproMene Bio
PeproMene Bio

Irvine, CA, US

Board Member· Board
Fuse Biotherapeutics
Fuse Biotherapeutics

Los Angeles, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Y Song's Career

PeproMene Bio
PeproMene Bio
Series A$4M52016Irvine, CA, US
Board Member· Board

Leadership at PeproMene Bio

Larry KwakLarry KwakBoard Member
Bryan KimBryan KimCEO

Similar to PeproMene Bio

Immpact BioImmpact BioCamarillo, CA, USCAR T-Cell Therapyest. 2017Immpact BioCamarillo, CA, US · est. 2017

ImmPACT Bio: Innovating transformative CAR-T cell therapies for advanced cancer patients.

Series B · $129M105
ManaT BioManaT BioBaltimore, MD, USImmunotherapyest. 2020ManaT BioBaltimore, MD, US · est. 2020

Based in Baltimore, ManaT Bio is a biotech firm specializing in genetic and immunological therapies.

Series D · $72.1M50
OncoPepOncoPepNorth Andover, MA, USCancer Therapies, Immunotherapiesest. 2010OncoPepNorth Andover, MA, US · est. 2010

OncoPep, Inc. develops targeted immunotherapies and tech for cancer prevention in the healthcare industry.

Public · $28.4M36
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Fuse Biotherapeutics
Fuse Biotherapeutics
Seed$9.5M52021Los Angeles, CA, US
Co-Founder

Leadership at Fuse Biotherapeutics

Brian RabinovichBrian RabinovichCo-Founder
Jeffrey TakimotoJeffrey TakimotoCo-Founder
Evren AliciEvren AliciCo-Founder

Similar to Fuse Biotherapeutics

Duet BioTherapeuticsDuet BioTherapeuticsPasadena, CA, USCancer Treatments, Immunotherapiesest. 2019Duet BioTherapeuticsPasadena, CA, US · est. 2019

Scopus BioPharma: Innovating targeted immunotherapies for treatment-resistant cancers.

Public · $200k8
LTZ TherapeuticsLTZ TherapeuticsSan Francisco, CA, USImmunotherapy, Therapeuticsest. 2022LTZ TherapeuticsSan Francisco, CA, US · est. 2022

LTZ: Innovating immunotherapies for cancer and diseases with unmet clinical needs.

Seed · $27M16
Modifi BioModifi BioNew Haven, CT, USCancer Therapeuticsest. 2021Modifi BioNew Haven, CT, US · est. 2021

Modifi Biosciences: Pioneering DNA modification for innovative cancer therapeutics.

Seed · $13.1M34
PineTree TherapeuticsPineTree TherapeuticsCambridge, MA, USBiotech Therapiesest. 2019PineTree TherapeuticsCambridge, MA, US · est. 2019

PineTree Therapeutics: Innovating biotech therapies in Oncology and Immuno-oncology.

Series B · $23.5M17

Paul Y Song's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Paul Y Song

Christopher C ReegChristopher C ReegBoard Member · Fuse MedicalJames BaulerJames BaulerCEO · Fuse OncologyRachel LiawRachel LiawCo-Founder · Fuse InventoryMike RoggeroMike RoggeroBoard Member · Fuse